ZIP7 Antibody - #DF4635

Fig. 2. MAM structure is essential for SLC39A7-NLRX1 complex formation and NP cell proliferation by maintaining mitochondrial Zn2+ homeostasis. (A) Confocal analysis of TOMM20 and CANX with IF staining in human NP cells isolated from health NP tissues following the treatments of PBS or TBHP with MFN2 knockdown or not, scale bar: 10 μm. (B) MAM structure analysis by TEM in human NP cells isolated from health NP tissues following the treatments of PBS or TBHP with MFN2 knockdown or not, scale bar: 1 μm. (C) Endogenous protein immunoprecipitated (IP) from NP cells isolated from health NP tissues with MFN2 knockdown or not, followed by western blotting, IP with anti-NLRX1 antibody. (D) Protein lysates extracted specially in mitochondria and cytoplasm of human NP cells isolated from health NP tissues with MFN2 knockdown or not, followed by western blotting. (E) Zinc distribution in primary human NP cells isolated from health NP tissues with MFN2 knockdown or not, detected by FluoZin™-3-AM labelling and confocal fluorescence microscope, scale bar: 10 μm. (F) Mitochondrial morphology analysis by fluorescence microscope with MitoTracker Red CMXRos label in primary human NP cells isolated from health NP tissues following the treatments of PBS or TBHP with MFN2 knockdown or not, scale bar: 5 μm. (G, H) Protein expressions of cell senescence indicators (TP53, CDKN2A) and extracellular matrix (COL2A1) in primary human NP cells isolated from health NP tissues following the treatments of PBS or TBHP with MFN2 knockdown or not, as determined by western blotting. (I-K) Cell senescence (SA-GLB1/β-gal staining) and cell proliferation (EdU incorporation) in primary human NP cells isolated from health NP tissues following the treatments of PBS or TBHP with MFN2 knockdown or not, scale bar: 100 μm (white light images), 200 μm (IF images). Data are represented as mean ± SD. *p